medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2017, Number 3

<< Back Next >>

An Med Asoc Med Hosp ABC 2017; 62 (3)

Highlights for the treatment for metastatic melanoma; state of the art

Camacho LCP, Gerson CR, Góngora JMÁ, Villalobos PA, Blanco VYC, López RO

Language: Spanish
References: 31
Page: 196-207
PDF size: 224.12 Kb.


ABSTRACT

Malignant melanoma tumor originated from neural crest melanocytes, represented 4% of all malignant tumors of the skin, but is responsible for 80% of deaths from cancer in this organ. Most melanomas are located in the skin (95%) and less common in the mucous membranes (oral, gastrointestinal, genital), the retina or the meninges (5%), 3% of patients develop hidden melanomas (metastatic disease without evidence of primary tumor). The rates of survival to one year are historically 59% for the M1a disease and 41% for the M1c illness (Before the time of immunotherapy or targeted therapies). Chemotherapy treatment is an active tool for patients with this diagnosis, but don’t provide survival changes, the advent of targeted therapies like tyrosine kinase inhibitors directed against BRAF mutation has changed the prognosis today, the role of immunotherapy offers a promising alternative treatment for this devastating disease. The present review highlights treatment strategies for metastatic melanoma that without doubt, represent hope for patients.


REFERENCES

  1. Secretaría de Salud. Dirección General de Epidemiología. Registro Histopatológico de Neoplasias Malignas, 2001.

  2. Martínez-Said H, Cuéllar-Hubbe M, Barrón-Velásquez E, Padilla RA, Herrera-Gómez A, López-Graniel CM. Epidemiology of cutaneous melanoma in Mexico (1982-2002). Eur J Surg Oncol. 2004; 30: 163.

  3. Curin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005; 353 (20): 2135-2147.

  4. Herrera NE, Aco AY. Melanoma en México: artículo de revisión. Revista de Especialidades Médico-Quirúrgicas. 2010; 15 (3): 161-164.

  5. Rosas SH, Baca T, Muñoz D, Muñoz F, Muñoz G. Estudio clínico, epidemiológico e histopatológico de melanoma maligno. Serie de 31 Casos. CIMEL. 2003; 8 (1): 23-27.

  6. Martínez SH. El primer Consenso Nacional de Expertos en Melanoma. Gac Mex Oncol. 2005; 4 (2): 11-13.

  7. Dennis LK. Analysis of the melanoma epidemic, both apparent and real. Arch Dermatol. 1999; 135: 275-280.

  8. Wong JH, Wanek L, Chang LJ, Goradia T, Morton D. The importance of anatomic site in prognosis in patients with cutaneous melanomas. Arch Surg. 1991; 126: 486-489.

  9. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27 (36): 6199-6206.

  10. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomized, double-blind, phase 3 trial. Lancet Oncol. 2015; 16 (5): 522-530.

  11. Bartlett EK, Karakousis GC. Current staging and prognostic factors in melanoma. Surg Oncol Clin N Am. 2015; 24 (2): 215-227.

  12. Bartlett EK, Gimotty P. Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy. Ann Surg Oncol. 2014; 21 (2): 643-649.

  13. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015; 16 (5): 522-530.

  14. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999; 17 (9): 2745-2751.

  15. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000; 18 (1): 158-166.

  16. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380 (9839): 358-365.

  17. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008; 26 (12): 2046-2051.

  18. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39 (1): 1-10.

  19. Tsai KK, Daud AI. The role of anti-PD-1/PD-L1 agents in melanoma. Drugs. 2015; 75 (6): 563-575.

  20. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364: 517-526.

  21. Curran MA, Montalvo W, Yagita H, Allison JP. PPD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA. 2010; 107 (9): 4275-4280.

  22. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2010; 366: 2455-2465.

  23. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013; 31: 616-622.

  24. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM et al. Nivolumab plus Ipilimumab in advanced melanoma. N Engl J Med. 2013; 369: 122-133.

  25. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014; 20: 5064-5074.

  26. Robert C, Schachter J, Long GV, Arance A, Jacques J, Mortier L et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372: 2521-2532.

  27. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermoth D et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015; 372: 2006-2017.

  28. Larkin J, Chiarion-Sileni V, Gonzalez R, Jacques J, Coney L, Lao CD et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373: 23-34.

  29. Hugo W, Zaretsky JM, Sun L, Song C, Homet B, Hu-Lieskovan S et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016; 165 (Issue 1): 35-44.

  30. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015; 33 (25): 2780-2788.

  31. A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202/MK-3475-037/KEYNOTE-037/ECHO-202). [Consultado 04 de julio 2017] Available in: /07/17. https://clinicaltrials.gov/ct2/show/NCT02178722




2020     |     www.medigraphic.com